AR060974A1 - Compuesto de 4-piridinona, su uso para la preparacion de un medicamento, composicion farmaceutica que lo comprende, proceso para su preparacion y proceso para la preparacion de un compuesto intermediario de utilidad en el anterior - Google Patents

Compuesto de 4-piridinona, su uso para la preparacion de un medicamento, composicion farmaceutica que lo comprende, proceso para su preparacion y proceso para la preparacion de un compuesto intermediario de utilidad en el anterior

Info

Publication number
AR060974A1
AR060974A1 ARP070102297A ARP070102297A AR060974A1 AR 060974 A1 AR060974 A1 AR 060974A1 AR P070102297 A ARP070102297 A AR P070102297A AR P070102297 A ARP070102297 A AR P070102297A AR 060974 A1 AR060974 A1 AR 060974A1
Authority
AR
Argentina
Prior art keywords
preparation
pharmaceutical composition
piridinone
composite
medicinal product
Prior art date
Application number
ARP070102297A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP06381025A external-priority patent/EP1862459A1/en
Priority claimed from EP07380072A external-priority patent/EP1967515A1/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR060974A1 publication Critical patent/AR060974A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/68—One oxygen atom attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Compuesto de 4-piridinona, de formula 1 en la que: R1 representa halo, CF3 u OCF3; R4 representa halo; uno de R2 y R3 representa metilo y el otro representa -(CH2)nOH o -HC=N-OR5; R5 representa H o alquilo C1-3; o un derivado farmacéuticamente aceptable del mismo. Su uso para la preparacion de un medicamento para el tratamiento de la malaria y composicion farmacéutica que lo comprende. Proceso para su preparacion y proceso para la preparacion de un compuesto intermediario de utilidad en el anterior.
ARP070102297A 2006-05-31 2007-05-29 Compuesto de 4-piridinona, su uso para la preparacion de un medicamento, composicion farmaceutica que lo comprende, proceso para su preparacion y proceso para la preparacion de un compuesto intermediario de utilidad en el anterior AR060974A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06381025A EP1862459A1 (en) 2006-05-31 2006-05-31 Novel heterocyclic compounds
EP07380072A EP1967515A1 (en) 2007-03-08 2007-03-08 Heterocyclic compounds

Publications (1)

Publication Number Publication Date
AR060974A1 true AR060974A1 (es) 2008-07-23

Family

ID=38480438

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070102297A AR060974A1 (es) 2006-05-31 2007-05-29 Compuesto de 4-piridinona, su uso para la preparacion de un medicamento, composicion farmaceutica que lo comprende, proceso para su preparacion y proceso para la preparacion de un compuesto intermediario de utilidad en el anterior

Country Status (17)

Country Link
US (2) US7674808B2 (es)
EP (1) EP2024332A1 (es)
JP (1) JP2009538873A (es)
KR (1) KR20090012342A (es)
AR (1) AR060974A1 (es)
AU (1) AU2007267093A1 (es)
BR (1) BRPI0711783A2 (es)
CA (1) CA2653872A1 (es)
CR (1) CR10492A (es)
EA (1) EA200870545A1 (es)
IL (1) IL195158A0 (es)
MA (1) MA30487B1 (es)
MX (1) MX2008015291A (es)
NO (1) NO20085087L (es)
PE (1) PE20080453A1 (es)
TW (1) TW200817331A (es)
WO (1) WO2007138048A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
DK1880001T3 (da) 2005-05-31 2011-09-12 Iams Company Feline probiotiske lactobacilli
CA2607949C (en) 2005-05-31 2012-09-25 Thomas William-Maxwell Boileau Feline probiotic bifidobacteria
AU2008211600B8 (en) 2007-02-01 2014-02-13 Mars, Incorporated Method for decreasing inflammation and stress in a mammal using glucose antimetabolites, avocado or avocado extracts
WO2009068623A1 (en) * 2007-11-30 2009-06-04 Glaxo Group Limited Crystalline form of an antimalarial compound
US9771199B2 (en) * 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
US9232813B2 (en) * 2008-07-07 2016-01-12 The Iams Company Probiotic supplement, process for making, and packaging
EP2246329A1 (en) 2009-01-19 2010-11-03 Glaxo Group Limited 4(1H)-pyridinone derivatives and their use as antimalaria agents
WO2010081904A1 (en) 2009-01-19 2010-07-22 Glaxo Group Limited 4 ( 1h) -pyridinone derivatives and their use as antimalaria agents
TW201039834A (en) 2009-02-20 2010-11-16 Glaxo Group Ltd Novel heterocyclic compounds
WO2010142741A1 (en) * 2009-06-12 2010-12-16 Glaxo Group Limited Phenylpyridylpyridones for use as antimalarial agents
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
US10426476B2 (en) * 2014-09-26 2019-10-01 Ethicon Llc Circular fastener cartridges for applying radially expandable fastener lines
JOP20180072A1 (ar) 2014-09-11 2019-01-30 Lilly Co Eli علاج الأعراض المرتبطة بالعلاج بالحرمان من الأندروجين
WO2016169908A1 (en) * 2015-04-21 2016-10-27 Glaxosmithkline Intellectual Property Development Limited Uracil derivatives for the treatment of malaria
GB201809627D0 (en) * 2018-06-12 2018-07-25 Biorelevant Com Ltd Methods for preparing buffer solutions suitable for in vitro drug dissolution testing, drug solubility testing and/or drug profiling

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9005518D0 (en) 1990-03-12 1990-05-09 Wellcome Found Heterocyclic compounds
US5403934A (en) * 1990-03-12 1995-04-04 Burroughs Wellcome Co. Heterocyclic compounds
GB9100465D0 (en) * 1991-01-09 1991-02-20 Hider Robert C Pharmaceutical compositions

Also Published As

Publication number Publication date
CA2653872A1 (en) 2007-12-06
TW200817331A (en) 2008-04-16
EP2024332A1 (en) 2009-02-18
JP2009538873A (ja) 2009-11-12
MX2008015291A (es) 2008-12-12
US20080021073A1 (en) 2008-01-24
KR20090012342A (ko) 2009-02-03
BRPI0711783A2 (pt) 2011-11-29
US20070281977A1 (en) 2007-12-06
US7629365B2 (en) 2009-12-08
WO2007138048A1 (en) 2007-12-06
US7674808B2 (en) 2010-03-09
AU2007267093A1 (en) 2007-12-06
IL195158A0 (en) 2009-08-03
NO20085087L (no) 2009-02-20
CR10492A (es) 2009-01-27
MA30487B1 (fr) 2009-06-01
PE20080453A1 (es) 2008-05-29
EA200870545A1 (ru) 2009-12-30

Similar Documents

Publication Publication Date Title
AR060974A1 (es) Compuesto de 4-piridinona, su uso para la preparacion de un medicamento, composicion farmaceutica que lo comprende, proceso para su preparacion y proceso para la preparacion de un compuesto intermediario de utilidad en el anterior
CL2019000209A1 (es) Formulación novedosa administrable por la vía oral.
ECSP088405A (es) Nuevos derivados de pirimidina y su uso en terapia, así como el uso de derivados de pirimidina en la fabricación de un medicamento para la prevención y/o tratamiento de la enfermedad de alzheimer
SV2005001920A (es) " compuestos nucleosidos para el tratamiento de infecciones virales "
UY29085A1 (es) Derivados de pirimidina 4-sulfonamido sustituidos, compuestos intermedios para su preparación, procedimientos de preparación, composiciones medicinales conteniéndolos y aplicaci0nes
AR071187A1 (es) Compuesto de arilmetil-tiazinamina, composicion farmaceutica que lo comprende y su uso para preparar un medicamento para el tratamiento de la enfermedad de alzheimer
AR077638A1 (es) Compuesto de (metanosulfonil -piperidin )-( alcoxi-aril) -tetrahidro- piridina , composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para el tratamiento de diabetes u obesidad
AR077277A1 (es) Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer
AR053162A1 (es) Compuesto 5 - oxo - pirrolidin sustituido, composicion farmaceutica que lo comprende y su uso para preparar un medicamento para el tratamiento del glaucoma.
AR074632A1 (es) Compuesto de amidofenoxiindazol, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util en el tratamiento de cancer
DOP2009000124A (es) Derivados de benzamida como receptores agonista ep4
CL2007003604A1 (es) Composicion farmaceutica para administrar oral que comprende el compuesto 17-aminogeldanamicina amorfo; y su uso en el tratamiento del cancer.
BRPI0610850A2 (pt) derivados de Ácido aril alquila, composiÇço farmacÊutica, medicamento, bem como uso dos referidos derivados
PE20070541A1 (es) Compuestos y composiciones que comprenden isoindol-imidas
EA200802390A1 (ru) Конъюгаты аналогов азиридилэпотилона и фармацевтические композиции, содержащие их
AR054129A1 (es) Derivados de 2, 6-quinolinilo, una preparacion farmaceutica que los contiene y su empleo en la fabricacion de medicamentos para el tratamiento de enfermedades dependientes de integrinas alfa4beta1 y/o alfa4beta7
CL2008000738A1 (es) Compuestos derivados de malonamida; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de la depresion, enfermedad de parkinson y alzheimer, entre otras enfermeda
TW200745122A (en) New compounds I
SG158863A1 (en) Intravenous formulations of pde-5 inhibitors
AR077139A1 (es) Composiciones farmaceuticas utiles para tratar el vch
EA201170512A1 (ru) Композиция для перорального введения
CL2011001413A1 (es) Compuestos derivados de 5-amino-2-(1-hidroxi-etil)-tetrahidropirano; composicion farmaceutica que comprende a uno de los compuestos; y su uso en la preparacion de medicamentos para la prevencion o el tratamiento de una infeccion bacteriana.
AR073265A1 (es) Uso de dronedarona para la preparacion de un medicamento para la prevencion de ictus o ataque isquemico transitorio
TW200800984A (en) New compounds
SA112330457B1 (ar) مشتقات فينيل- ايزواوكسازول وعملية تحضيرها

Legal Events

Date Code Title Description
FA Abandonment or withdrawal